COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,015 Articles (22,627 medRxiv, 8,388 bioRxiv)

Most recent first Previous |  Page 852: Articles 8511-8520  | Next

Lower Risk of Paediatric Inflammatory Multisystem Syndrome (PIMS-TS) with the Delta variant of SARS-CoV-2
Cohen, J. M., Ladhani, S., Carter, M. J., Cheung, R., Evelina PIMS-TS Study Group
10.1101/2022.03.13.22272267 — Posted: 2022-03-14
Broad Cross-reactive IgA and IgG Against Human Coronaviruses in Milk Induced by COVID-19 Vaccination and Infection
Wang JIong, J., Young, B. E., Li, D., Seppo, A. E., Zhou, Q., Wiltse, A., Nowak-wegrzyn, A., Murphy, K., Widrick, K., Diaz, N., CruzVasquez, J., Jarvinen, K. M., Zand, M. S.
10.1101/2022.03.13.22272281 — Posted: 2022-03-14
C allele of rs479200 of the host EGLN1 gene - a risk factor for severe COVID-19 (pilot study)
Harit, R., De, S., Singh, P. K., Kashyap, D., Kumar, M., Sahu, D., Yadav, C. P., Mohan, M., Singh, V., Tomar, R. S., Pandey, K. C., Vashisht, K.
10.1101/2022.03.11.22272214 — Posted: 2022-03-14
Understanding adherence to self-isolation in the first phase of COVID-19 response
Robin, C., Reynolds, R., Lambert, H., Hickman, M., Rubin, J., Smith, L. E., Yardley, L., Cai, S., Zhang, T., Mook, P., McManus, O., Lasseter, G., Compston, P., Denford, S., Zhang, J., Amlot, R., Oliver, I.
10.1101/2022.03.14.22272273 — Posted: 2022-03-14
A broad and potent neutralization epitope in SARS-related coronaviruses
Yuan, M., Zhu, X., He, W.-t., Zhou, P., Kaku, C. I., Capozzola, T., Zhu, C. Y., Yu, X., Liu, H., Yu, W., Hua, Y., Tien, H., Peng, L., Song, G., Cottrell, C., Schief, W. R., Nemazee, D., Walker, L. M., Andrabi, R., Burton, D., Wilson, I. A.
10.1101/2022.03.13.484037 — Posted: 2022-03-14
Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events
Ou, J., Lan, W., Wu, X., Zhao, T., Duan, B., Yang, P., Ren, Y., Quan, L., Zhao, W., Seto, D., Chodosh, J., Wu, J., Zhang, Q.
10.1101/2022.03.13.484129 — Posted: 2022-03-14
Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant
Tai, W., Chai, B., Feng, S., Zhuang, X., Ma, J., Pang, M., Pan, L., Yang, Z., Tian, M., Cheng, G.
10.1101/2022.03.13.484123 — Posted: 2022-03-14
Accelerating PERx Reaction Enables Covalent Nanobodies for Potent Neutralization of SARS-Cov-2 and Variants
Yu, B., Li, S., Tabata, T., Wang, N., Kumar, G. R., Liu, J., Ott, M. M., Wang, L.
10.1101/2022.03.11.483867 — Posted: 2022-03-14
Presence of Mediastinal Lymphadenopathy in Hospitalized Covid-19 Patients in a Tertiary Care Hospital in Pakistan - A cross-sectional study
Malik, A. A., Bhatti, F. S., Malik, A. A.
10.1101/2022.03.10.22272193 — Posted: 2022-03-14
ACE2 gene expression and inflammatory conditions in periodontal microenvironment of COVID-19 patients with and without diabetes evaluated by qPCR
Bachtiar, B. M., Bachtiar, E. W., Sunarto, H., Soeroso, Y., Sulijaya, B., Theodorea, C. F., Pratomo, I. P., Yudhistira, , Kusumaningrum, A., Efendi, D., Apriyanti, E., Deviana, A., Utami, N. R., Andriyani, A. D.
10.1101/2022.03.10.22271304 — Posted: 2022-03-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).